These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 25968495)

  • 1. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
    Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
    Bagriy AE; Schukina EV; Samoilova OV; Pricolota OA; Malovichko SI; Pricolota AV; Bagriy EA
    Adv Ther; 2015 Feb; 32(2):108-19. PubMed ID: 25700807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
    Wikstrand J; Wedel H; Castagno D; McMurray JJ
    J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
    Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
    Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
    Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
    Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):81-90. PubMed ID: 27859924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
    Riccioni G; Masciocco L; Benvenuto A; Saracino P; De Viti D; Massari F; Meliota G; Buta F; Speziale G
    Pharmacology; 2013; 92(5-6):276-80. PubMed ID: 24296869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y; Asai K; Furuse E; Nakamura S; Murai K; Tsukada YT; Shimizu W
    Int J Chron Obstruct Pulmon Dis; 2015; 10():515-23. PubMed ID: 25784798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is carvedilol better than other beta-blockers for heart failure?
    Rain C; Rada G
    Medwave; 2015 Jun; 15 Suppl 1():e6168. PubMed ID: 26135382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
    Fröhlich H; Torres L; Täger T; Schellberg D; Corletto A; Kazmi S; Goode K; Grundtvig M; Hole T; Katus HA; Cleland JGF; Atar D; Clark AL; Agewall S; Frankenstein L
    Clin Res Cardiol; 2017 Sep; 106(9):711-721. PubMed ID: 28434020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
    Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
    Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
    Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.
    Lin TY; Chen CY; Huang YB
    Int J Cardiol; 2017 Mar; 230():378-383. PubMed ID: 28041715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
    Sessa M; Mascolo A; Mortensen RN; Andersen MP; Rosano GMC; Capuano A; Rossi F; Gislason G; Enghusen-Poulsen H; Torp-Pedersen C
    Eur J Heart Fail; 2018 Mar; 20(3):548-556. PubMed ID: 29159953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Carvedilol versus β1-selective β blockers (bisoprolol, metoprolol, and nebivolol) in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Seo GW; Kim DK; Kim KH; Seol SH; Jin HY; Yang TH; Ahn Y; Jeong MH; Song PS; Kim DI;
    Am J Cardiol; 2015 Nov; 116(10):1502-8. PubMed ID: 26520013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
    Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lubsen J; Lutiger B; Metra M; Remme WJ; Torp-Pedersen C; Scherhag A; Skene A;
    Lancet; 2003 Jul; 362(9377):7-13. PubMed ID: 12853193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).
    DiNicolantonio JJ; Lavie CJ; Fares H; Menezes AR; O'Keefe JH
    Am J Cardiol; 2013 Mar; 111(5):765-9. PubMed ID: 23290925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.